Research programme: haemophilia gene therapy - Oxford BioMedica

Drug Profile

Research programme: haemophilia gene therapy - Oxford BioMedica

Alternative Names: ReQuinate

Latest Information Update: 27 Jan 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oxford BioMedica
  • Class Gene therapies
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Haemophilia A

Most Recent Events

  • 15 Aug 2008 Gene-based therapeutic for the treatment of haemophillia A is available for licensing worldwide (http://www.oxfordbiomedica.co.uk)
  • 28 Aug 2007 Preclinical development is ongoing
  • 22 Jun 2005 Data presented at the 8th Annual Meeting of the American Society of Gene Therapy (ASGT-2005) have been added to the Drug delivery systems pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top